ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy
NCT ID: NCT05863221
Last Updated: 2023-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2023-05-09
2024-10-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Group 1: ZYNRELEF® up to 200 mg/ 6mg ( 7ml vial) via instillation at all incision sites in addition to 30 ml of 0.5% Ropivacaine + 10mg dexamethasone. Postoperatively, intermittent IV acetaminophen will be administered as per need till discharge.
Group 2: 30 ml of 0.5% Ropivacaine and 10mg dexamethasone into all surgical sites and intermittent IV acetaminophen as per need till discharge.
Primary Objective:
To compare the efficacy and duration of analgesia achieved following the instillation of ZYNRELEF® all incision sites in addition to Ropivacaine with dexamethasone + postoperative IV acetaminophen, to the standard treatment of Ropivacaine with dexamethasone + postoperative IV acetaminophen in subjects undergoing laparoscopic sleeve gastrectomy.
Secondary Objectives:
1. To evaluate additional efficacy parameters, including opioid load, in this study population.
2. To determine the impact of ZYNRELEF® on the cost of pain management.
3. To assess the time taken to resume exercise after discharge.
4. To assess the adverse events reported following the use of ZYNRELEF®.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
NCT06349772
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE
NCT06109428
Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery
NCT02969187
Efficacy of Preventive Ketamine on Postoperative Pain
NCT04908579
ZYNRELEF vs Continuous Catheter for Pain Management Following Shoulder Arthroplasty
NCT07280195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
ZYNRELEF® up to 200 mg/ 6mg ( 7ml vial) via instillation at all incision sites in addition to 30 ml of 0.5% Ropivacaine + 10mg dexamethasone. Postoperatively, intermittent IV acetaminophen will be administered as per need till discharge.
ZYNRELEF 200Mg-6Mg Extended-Release Solution
ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
Group 2
30 ml of 0.5% Ropivacaine and 10mg dexamethasone into all surgical sites and intermittent IV acetaminophen as per need till discharge.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZYNRELEF 200Mg-6Mg Extended-Release Solution
ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Is able to adhere to the study visit schedule and complete all study assessments.
3. Is male or female or other, and ≥18 years of age at screening.
4. Is scheduled to undergo laparoscopic sleeve gastrectomy under general anesthesia
5. Has an American Society of Anesthesiologists Physical Status of I, II, or III.
6. Female subjects are eligible only if all the following apply:
* Not pregnant (female subjects of childbearing potential must have a negative urine pregnancy test at screening and on Day 1 before surgery).
* Not lactating.
* Not planning to become pregnant during the study.
* Is surgically sterile (eg, has had a bilateral tubal ligation); or is at least 2 years postmenopausal; or is in a monogamous relationship with a partner who is surgically sterile; or is practicing abstinence or agrees to use double-barrier contraception in the event of sexual activity; or is using an insertable, injectable, transdermal, or combination oral contraceptive approved by applicable regulatory authorities for greater than 2 months prior to screening and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days after study drug administration. Note: women in only a same-sex relationship do not need to meet this criterion.
Exclusion Criteria
2. Has been administered Ropivacaine within 5 days prior to the scheduled surgery.
3. Has been administered any local anesthetic within 72 hours prior to the scheduled surgery, other than for pretreatment prior to a needle placement, to treat an AE that occurs after signing the ICF, or to decrease venous irritation (eg, caused by propofol, in which case no more than a single administration of lidocaine 1% 20 mg IV may be administered).
4. Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of the study drug (whichever is longer). Note that for purposes of this exclusion criterion, inhaled, ophthalmic, and over-the-counter steroids are not considered systemic.
5. Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments. Conditions may include but are not limited to, any of the following:
1. History of asthma or urticarial/ allergic-type reactions after taking aspirin or NSAIDs.
2. History of clinically significant cardiac abnormality such as myocardial infarction within 6 months prior to signing the ICF, New York Heart Association class III or IV, or clinically significant abnormalities of electrocardiogram (ECG) or cardiac function.
3. History of coronary artery bypass graft surgery within 12 months prior to signing the ICF.
4. History of severe liver function impairment as defined by Child-Pugh Class C, having an aspartate aminotransferase \>3 × the upper limit of normal (ULN) or having an alanine aminotransferase \>3 × ULN.
5. History of severe kidney function impairment as defined by creatinine clearance (Cockcroft-Gault) \<30 mL/min, being on dialysis, and/or having a serum creatinine \>2 × ULN.
6. History of known or suspected coagulopathy or uncontrolled anticoagulation (PLT count \<100,000/μL; hemoglobin \<12 g/dL; or hematocrit \<35%).
7. Loss of sensation in extremities or significant peripheral neuropathy.
6. As per subject history and/or medical records, has active infection or is currently undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).
7. Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
8. Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
9. Has a known or suspected history of drug abuse over the last 6 months, a positive drug screen on the day of surgery, or a recent history of alcohol abuse over the last 6 months. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor.
10. Previously participated in a ZYNRELEF® or HTX-011 study.
11. Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives (whichever is longer) prior to surgery, or is planning to take part in another clinical trial while participating in this study.
12. Has undergone 3 or more surgeries within 12 months prior to signing the Informed Consent Form, other than for diagnostic procedures (eg, colonoscopy)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heron Therapeutics
INDUSTRY
Dr. Yannis Raftopoulos
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Yannis Raftopoulos
Director of Weight Management Program
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yannis Raftopoulos, MD
Role: PRINCIPAL_INVESTIGATOR
Holyoke Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Holyoke Medical Center
Holyoke, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Heron Holyoke 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.